Vertex Historical Balance Sheet


USD 294.52  2.36  0.81%   

Trend analysis of Vertex Pharmaceutic balance sheet accounts such as Inventories of 381 M, Receivables of 1.2 B, Accounts Payable of 210.4 M or Accumulated Other Comprehensive Income of 20.6 M provides information on Vertex Pharmaceutic's total assets, liabilities, and equity, which is the actual value of Vertex Pharmaceutic to its prevalent stockholders. By breaking down trends over time using Vertex Pharmaceutic balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year. Financial Statement Analysis is much more than just reviewing and breaking down Vertex Pharmaceutic prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vertex Pharmaceutic is a good buy for the upcoming year.
Also, please take a look at World Market Map.

About Vertex Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Vertex Pharmaceutic at a specified time, usually calculated after every quarter, six months, or one year. Vertex Pharmaceutic Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Vertex Pharmaceutic and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Vertex currently owns. An asset can also be divided into two categories, current and non-current.

Vertex Pharmaceutic Balance Sheet Chart

Vertex Pharmaceutic Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Vertex Pharmaceutic uses and utilizes its capital. It also shows what exactly a company owns and owes.
Vertex Pharmaceutic Deferred Revenue is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Deferred Revenue of 14.53 Million in 2021. Shareholders Equity is likely to rise to about 10.9 B in 2022, whereas Debt Non Current is likely to drop slightly above 415.6 M in 2022.

Total Assets

Total assets refers to the total amount of Vertex Pharmaceutic assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vertex Pharmaceutic books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; Investments; Goodwill and Intangible Assets; Property Plant and Equipment Net; [TaxAssets] and Trade and Non Trade Receivables.

Current Assets

Current assets of Vertex Pharmaceutic include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Vertex Pharmaceutic. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Shareholders Equity

A principal component of the balance sheet; in addition to Total Liabilities and Total Assets; that represents the total of all stockholders' equity (deficit) items; net of receivables from officers; directors; owners; and affiliates of the entity which are attributable to the parent.

Total Liabilities

Deferred Income Tax is recorded on Vertex Pharmaceutic balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on Vertex Pharmaceutic books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are Total Debt; Deferred Revenue; Trade and Non Trade Payables; Deposit Liabilities; and Tax Liabilities.
Most accounts from Vertex Pharmaceutic balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Vertex Pharmaceutic current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Also, please take a look at World Market Map.Vertex Pharmaceutic Deferred Revenue is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Deferred Revenue of 14.53 Million in 2021. Shareholders Equity is likely to rise to about 10.9 B in 2022, whereas Debt Non Current is likely to drop slightly above 415.6 M in 2022.
 2019 2020 2021 2022 (projected)
Receivables633.52 M885.35 M1.14 B1.23 B
Inventories167.5 M280.78 M353.1 M380.98 M

Vertex Pharmaceutic balance sheet Correlations

Click cells to compare fundamentals

Vertex Pharmaceutic Account Relationship Matchups

Vertex Pharmaceutic balance sheet Accounts

201720182019202020212022 (projected)
Inventories111.83 M124.36 M167.5 M280.78 M353.1 M380.98 M
Receivables310.25 M414.87 M633.52 M885.35 M1.14 B1.23 B
Accounts Payable73.99 M110.99 M87.61 M155.14 M195 M210.39 M
Total Assets3.55 B6.25 B8.32 B11.75 B13.43 B14.49 B
Current Assets2.65 B3.84 B4.82 B8.13 B9.56 B10.32 B
Cash and Equivalents1.67 B2.65 B3.11 B5.99 B6.79 B7.33 B
Shareholders Equity2.03 B4.44 B6.09 B8.69 B10.1 B10.9 B
Total Liabilities1.52 B1.81 B2.23 B3.06 B3.33 B3.6 B
Current Liabilities807.26 M1.12 B1.33 B1.88 B2.14 B2.31 B

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceutic without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Markets Map Now


Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Also, please take a look at World Market Map. Note that the Vertex Pharmaceutic information on this page should be used as a complementary analysis to other Vertex Pharmaceutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceutic price analysis, check to measure Vertex Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceutic is operating at the current time. Most of Vertex Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceutic's price. Additionally, you may evaluate how the addition of Vertex Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Money Managers
Screen money managers from public funds and ETFs managed around the world
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Is Vertex Pharmaceutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceutic. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
75.5 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Vertex Pharmaceutic is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceutic's value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceutic's market value can be influenced by many factors that don't directly affect Vertex Pharmaceutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.